Meeting NewsVideo

VIDEO: Patients with gout, type 2 diabetes require more aggressive management

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Machelle Manuel, PhD, vice president of medical scientific affairs at Ironwood Pharmaceuticals, discussed study findings that examined potential associations of type 2 diabetes and gout with clinical outcomes, as well as variations in gout severity, management and health care use among patients with both conditions.

Manuel noted that patients with both gout and type 2 diabetes were more likely to have a greater impact on health spending, with additional comorbidities and more severe gout than those without type 2 diabetes. She added that this suggests that patients with both conditions need careful monitoring and more aggressive gout management.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Machelle Manuel, PhD, vice president of medical scientific affairs at Ironwood Pharmaceuticals, discussed study findings that examined potential associations of type 2 diabetes and gout with clinical outcomes, as well as variations in gout severity, management and health care use among patients with both conditions.

Manuel noted that patients with both gout and type 2 diabetes were more likely to have a greater impact on health spending, with additional comorbidities and more severe gout than those without type 2 diabetes. She added that this suggests that patients with both conditions need careful monitoring and more aggressive gout management.

    See more from American College of Rheumatology Annual Meeting